Invesaro

Stocks Comparison

Cresco Labs vs Usana Health Sciences: revenue, profit, margins and growth compared

Cresco Labs brought in $655.8M of revenue in fiscal 2025, Usana Health Sciences $925.3M in fiscal 2025. Revenue changed by -9.5% at Cresco Labs and +8.3% at Usana Health Sciences on the year before, so Usana Health Sciences grew faster. Cresco Labs kept -20.6% of its revenue as net profit, Usana Health Sciences 1.2%. Free cash flow was $37.8M at Cresco Labs and $8.5M at Usana Health Sciences.

Side by side, latest fiscal year

CRLBFUSNA
Fiscal year endedFY2025 (December 31, 2025)FY2025 (January 3, 2026)
Revenue$655.8M$925.3M
Revenue growth-9.5%+8.3%
Net income-$135.4M$10.8M
Net margin-20.6%1.2%
Free cash flow$37.8M$8.5M
Free cash flow margin5.8%0.9%
Earnings per share (diluted)-$0.38$0.58
Cash$57.9M$158.4M
Debt$420.4Mn/a
Price to earningsn/a25.6
Market valuen/a$273.8M
Dividend yieldn/an/a
Rank by revenue in sector#185 of 742 · Health care#158 of 742 · Health care

Over the years

Revenue
CRLBF FY2020: $128.5MCRLBF FY2020: $476.3MCRLBF FY2021: $821.7MCRLBF FY2022: $842.7MCRLBF FY2023: $770.9MCRLBF FY2024: $724.3MCRLBF FY2025: $655.8MUSNA FY2018: $1.2BUSNA FY2019: $1.1BUSNA FY2020: $1.1BUSNA FY2022: $1.2BUSNA FY2022: $998.6MUSNA FY2023: $921MUSNA FY2023: $854.5MUSNA FY2025: $925.3MFY18FY19FY20FY21FY22FY23FY24FY25
CRLBF $655.8MUSNA $925.3M
Net income
CRLBF FY2020: -$43.2MCRLBF FY2020: -$102.2MCRLBF FY2021: -$319.6MCRLBF FY2022: -$212MCRLBF FY2023: -$175.5MCRLBF FY2024: -$74.4MCRLBF FY2025: -$135.4MUSNA FY2018: $126.2MUSNA FY2019: $100.5MUSNA FY2020: $124.7MUSNA FY2022: $116.5MUSNA FY2022: $69.4MUSNA FY2023: $63.8MUSNA FY2023: $42MUSNA FY2025: $10.8MFY18FY19FY20FY21FY22FY23FY24FY25
CRLBF -$135.4MUSNA $10.8M
Net margin
CRLBF FY2020: -33.6%CRLBF FY2020: -21.5%CRLBF FY2021: -38.9%CRLBF FY2022: -25.2%CRLBF FY2023: -22.8%CRLBF FY2024: -10.3%CRLBF FY2025: -20.6%USNA FY2018: 10.6%USNA FY2019: 9.5%USNA FY2020: 11.0%USNA FY2022: 9.8%USNA FY2022: 6.9%USNA FY2023: 6.9%USNA FY2023: 4.9%USNA FY2025: 1.2%FY18FY19FY20FY21FY22FY23FY24FY25
CRLBF -20.6%USNA 1.2%
Revenue growth
CRLBF FY2020: +270.5%CRLBF FY2021: +72.5%CRLBF FY2022: +2.6%CRLBF FY2023: -8.5%CRLBF FY2024: -6.0%CRLBF FY2025: -9.5%USNA FY2019: -10.8%USNA FY2020: +7.0%USNA FY2022: +4.6%USNA FY2022: -15.8%USNA FY2023: -7.8%USNA FY2023: -7.2%USNA FY2025: +8.3%FY19FY20FY21FY22FY23FY24FY25
CRLBF -9.5%USNA +8.3%
Free cash flow
CRLBF FY2020: -$116.9MCRLBF FY2020: -$95MCRLBF FY2021: -$79.4MCRLBF FY2022: -$64.3MCRLBF FY2023: $3.2MCRLBF FY2024: $113MCRLBF FY2025: $37.8MUSNA FY2018: $140.7MUSNA FY2019: $110.2MUSNA FY2020: $145.3MUSNA FY2022: $108.5MUSNA FY2022: $93.5MUSNA FY2023: $56.1MUSNA FY2023: $50.9MUSNA FY2025: $8.5MFY18FY19FY20FY21FY22FY23FY24FY25
CRLBF $37.8MUSNA $8.5M

Fiscal years as each company reports them; the two may end in different months.

Questions about Cresco Labs and Usana Health Sciences

Which is bigger by revenue, Cresco Labs or Usana Health Sciences?

Usana Health Sciences is bigger by revenue: $925.3M in fiscal 2025, against $655.8M for Cresco Labs in fiscal 2025.

Which keeps more of its revenue as profit, Cresco Labs or Usana Health Sciences?

Cresco Labs had a net margin of -20.6% in fiscal 2025; Usana Health Sciences had 1.2% in fiscal 2025.

Which grew revenue faster, Cresco Labs or Usana Health Sciences?

In their latest fiscal years revenue changed by -9.5% at Cresco Labs and +8.3% at Usana Health Sciences.

Where do these numbers come from?

From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.

More comparisons

Compare more companies